Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel

Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies.

More from Archive

More from Pink Sheet